The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

Santhera Pharmaceuticals has started launch preparations for its DMD drug Agamree (vamorolone) in the UK, after a ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Hold rating on Kymera Therapeutics (KYMR – Research ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...